Isoformix Inc.

Sugar Land, TX

UEI
NFTCN18E9BM5
CAGE
7VQ71
Primary NAICS
325413 In-Vitro Diagnostic Substance Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
202 Industrial Blvd #404, Sugar Land, TX 77478, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Clusterin glycosylation as diagnostic and prognostic biomarker for alzheimer's disease R43AG079709 National Institute on Aging (NIH) $384,767
Immunoplate-maldi MS platform and assays R43GM143964 National Institute of General Medical Sciences (NIH) $512,316
Apoe isoform-specific glycosylation as diagnostic and prognostic biomarker of alzheimer's disease R43AG069552 National Institute on Aging (NIH) $250,562
Clinical mass spectrometry test for apolipoprotein c-III proteoforms R43GM128459 National Institute of General Medical Sciences (NIH) $153,545

Similar vendors

Vendor Location Primary NAICS
Tymora Analytical Operations LLC UEI ZFFZKDYTF5Q9 West Lafayette, IN 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Adeptrix Corp UEI UD9UKVEQNV49 Boston, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Neurodex Inc. UEI CK9RG13HMKN5 Natick, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Seer, Inc. UEI ZJTLN42M9X85 Redwood City, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Vitan-Biotech LLC UEI ML5NLF9L1FP9 — 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Isoformix Inc. is a for-profit corporate entity that provides research and development services to the U.S. federal government through grant awards from the National Institutes of Health (NIH). Specifically, Isoformix develops diagnostic assays and platforms involving mass spectrometry to detect and analyze protein biomarkers.

Past federal grants awarded to Isoformix as the prime recipient include a $384,767 project grant from the NIH National Institute on Aging to develop a mass spectrometry immunoassay for detection of clusterin glycoprotein variants as potential biomarkers for Alzheimer's disease risk and prognosis. An additional $512,316 project grant was awarded by the NIH National Institute of General Medical Sciences to develop an immunoplate-MALDI mass spectrometry platform and proof-of-concept assays for proteoforms of six protein biomarkers like apolipoprotein E. Isoformix also received a $250,562 project grant from the NIH National Institute on Aging to study apolipoprotein E isoform-specific glycosylation patterns as diagnostic and prognostic biomarkers for Alzheimer’s disease. As a subrecipient, Isoformix partnered with Arizona State University on proteoform analysis of apolipoprotein C in relation to dyslipidemia and cardiovascular disease.

Quick answers

Is Isoformix Inc. registered in SAM.gov?

Yes. Isoformix Inc.'s SAM.gov registration is active through March 24, 2027.

What is Isoformix Inc.'s most recent federal award?

Isoformix Inc.'s most recent federal grant award is Clusterin glycosylation as diagnostic and prognostic biomarker for alzheimer's disease (R43AG079709), from National Institute on Aging (NIH), on June 15, 2023.

On GovTribe

See Isoformix Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login